O02 Developmental pharmacogenetics of SLCO2B1 on montelukast pharmacokinetics in chinese children
| العنوان: | O02 Developmental pharmacogenetics of SLCO2B1 on montelukast pharmacokinetics in chinese children |
|---|---|
| المؤلفون: | E Jacqz-Aigrain, H-Y Shi, Y. Zhou, K Wang, Wu Y-E, X-L Wang, M Kan, G-X Hao, X-M Yang, Su L-Q, Wei Zhao, Q Li, Y Zheng, Y-L Yang |
| المصدر: | Archives of Disease in Childhood. 104:e1.2-e1 |
| بيانات النشر: | BMJ, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, education.field_of_study, business.industry, Population, medicine.disease, Gastroenterology, NONMEM, Pharmacokinetics, Oral administration, Internal medicine, Pediatrics, Perinatology and Child Health, Medicine, business, education, CYP2C8, Montelukast, Pharmacogenetics, medicine.drug, Asthma |
| الوصف: | BackgroundMontelukast, a potent orally selective leukotriene-receptor antagonist, inhibits the action of cysteinyl-leukotriene in patients with asthma.Although pharmacokinetic studies of montelukast have been reported in Caucasian adults and children, and showed significant inter-individual variability on pharmacokinetics.None of pharmacokinetic study has been explored in Chinese children. Given the potential inter-ethnic difference, the purpose of this study was to evaluate the effects of developmental factors and pharmacogenetics of CYP2C8 and SLCO2B1on Montelukast pharmacokinetics in Chinese paediatric patients.MethodsAfter oral administration with montelukast, opportunistic samples were collected from asthma children and plasma concentrations were determined by high performance liquid chromatography coupled with fluorescence detector (HPLC-FLD) method. Population pharmacokinetic analysis was performed using a nonlinear mixed-effects model approach (NONMEM V 7.2.0) and variants of CYP2C8 and SLCO2B1 were genotyped.ResultsFifty patients (age range 0.7–10.0 years) with asthma were enrolled in this study. The clearance of montelukast was significantly higher in subjects with SLCO2B1 c.935GA and c.935AAgenotype compared withSLCO2B1 c.935GGsubjects (0.94±0.26 versus 0.77±0.21, p=0.020). Weight was also found to be significantly corrected with montelukast clearance (p 0.0001).ConclusionsThe developmental pharmacogenetics of montelukast in Chinese children was evaluated. Weight and SLCO2B1 genotype showed independently significant impacts on theclearanceofmontelukast.Disclosure(s)Nothing to disclose. |
| تدمد: | 1468-2044 0003-9888 |
| DOI: | 10.1136/archdischild-2019-esdppp.2 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::b042ed13aee7b075985b65df24890db1 https://doi.org/10.1136/archdischild-2019-esdppp.2 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........b042ed13aee7b075985b65df24890db1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14682044 00039888 |
|---|---|
| DOI: | 10.1136/archdischild-2019-esdppp.2 |